This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
ArQule, Inc. announced the initiation of a Phase 2, single agent trial with ARQ 197 in germ cell tumors (GCT), including testicular and non- central nervous system (non-CNS) tumors, and a Phase 1/2 clinical trial designed to evaluate the safety of ARQ 197 administered in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer (CRC) who possess the wild-type form of the KRAS gene.
We care about your feedback. Let us know how we can improve your CancerCompass experience.